MICHELLE GRIMES: Open Payments
NPI 1578881082 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,365 in 40 payments from 10 companies in 2025. Trend: 2023 $1,036 · 2024 $1,142 · 2025 $1,365
Food & beverage: $1,365
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 13 | $382 |
| Regeneron Healthcare Solutions, Inc. | 9 | $290 |
| AstraZeneca Pharmaceuticals LP | 3 | $209 |
| AERIN MEDICAL INC. | 3 | $188 |
| Optinose US, Inc. | 6 | $146 |
| GlaxoSmithKline, LLC. | 2 | $51 |
| Smith+Nephew, Inc. | 1 | $38 |
| Merck Sharp & Dohme LLC | 1 | $25 |
| Integra LifeSciences Corporation | 1 | $18 |
| Hikma Pharmaceuticals USA | 1 | $17 |
Products named: DUPIXENT, VIVAER STYLUS, Xhance, TEZSPIRE, NUCALA, KEYTRUDA QLEX, Integra, Ryaltris.
Industry payments across TX — which companies pay providers there.
